The Claim
Acute silencing of Angptl7 mRNA in adult mice via intravitreal siRNA administration reduces intraocular pressure by 2–4 mmHg within two weeks, demonstrating that inhibition of ANGPTL7 lowers intraocular pressure after developmental completion and is pharmacologically reversible.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adult mice, injecting a specific RNA molecule into the eye reduces eye pressure by 2–4 mmHg within two weeks by blocking the ANGPTL7 gene product, showing this effect occurs after development and can be reversed by stopping the treatment.
See the scientific wording
Acute silencing of Angptl7 mRNA in adult mice using intravitreal siRNA reduces intraocular pressure by 2–4 mmHg within two weeks, demonstrating that ANGPTL7 inhibition can lower eye pressure even after development is complete and is pharmacologically reversible.
When the ANGPTL7 protein is removed from the eye's drainage system, the mesh-like tissue that filters fluid becomes less stiff and allows more fluid to drain out, which lowers the pressure inside the eye.
What the research says
1 studyStudy: ANGPTL7, a therapeutic target for increased intraocular pressure and glaucoma
Scientists injected a special molecule into adult mice’s eyes to turn off the Angptl7 gene, and their eye pressure dropped by 2–4 mmHg — proving you can lower eye pressure even in fully grown eyes by blocking this gene.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.